Erschienen in:
01.12.2010 | Section introduction
Introduction: are current drug development programmes realising the full potential of new agents?
verfasst von:
Stephen RD Johnston, Ajay Bhatanager
Erschienen in:
Breast Cancer Research
|
Sonderheft 4/2010
Einloggen, um Zugang zu erhalten
Excerpt
Just like the 2009 Edinburgh Controversies meeting, the final two sessions addressed the question of whether current drug development programmes for new agents in breast cancer are realising their full potential. However, this time the approach was to assess how various different clinical studies/novel drugs are prioritised by either the pharmaceutical industry or by academic groups and investigators, and in addition how clinical trials in breast cancer are evolving in an era of targeted therapeutics. As in previous years, this was followed by an expert panel of representatives who debated the issues in an interactive fashion with the audience. …